| pubmed-article:21531981 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C0017696 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C0443199 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C0457784 | lld:lifeskim |
| pubmed-article:21531981 | lifeskim:mentions | umls-concept:C1998811 | lld:lifeskim |
| pubmed-article:21531981 | pubmed:issue | 25 | lld:pubmed |
| pubmed-article:21531981 | pubmed:dateCreated | 2011-6-24 | lld:pubmed |
| pubmed-article:21531981 | pubmed:abstractText | ?-glucans have been reported to function as a potent adjuvant to stimulate innate and adaptive immune responses. However, ?-glucans from different sources are differential in their structure, conformation, and thus biologic activity. Different preparations of ?-glucans, soluble versus particulate, further complicate their mechanism of action. Here we show that yeast-derived particulate ?-glucan activated dendritic cells (DCs) and macrophages via a C-type lectin receptor dectin-1 pathway. Activated DCs by particulate ?-glucan promoted Th1 and cytotoxic T-lymphocyte priming and differentiation in vitro. Treatment of orally administered yeast-derived particulate ?-glucan elicited potent antitumor immune responses and drastically down-regulated immunosuppressive cells, leading to the delayed tumor progression. Deficiency of the dectin-1 receptor completely abrogated particulate ?-glucan-mediated antitumor effects. In contrast, yeast-derived soluble ?-glucan bound to DCs and macrophages independent of the dectin-1 receptor and did not activate DCs. Soluble ?-glucan alone had no therapeutic effect but significantly augmented antitumor monoclonal antibody-mediated therapeutic efficacy via a complement activation pathway but independent of dectin-1 receptor. These findings reveal the importance of different preparations of ?-glucans in the adjuvant therapy and allow for the rational design of immunotherapeutic protocols usable in clinical trials. | lld:pubmed |
| pubmed-article:21531981 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21531981 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21531981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21531981 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21531981 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21531981 | pubmed:issn | 1528-0020 | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:KuoZ FZF | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:IwakuraYoichi... | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:SaijoShinobuS | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:LiBingB | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:YannelliJohn... | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:DingChuanlinC | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:QiChunjianC | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:KloeckerGoetz... | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:GunnLaceyL | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:CaiYihuaY | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:VasilakosJohn... | lld:pubmed |
| pubmed-article:21531981 | pubmed:author | pubmed-author:QianKeqingK | lld:pubmed |
| pubmed-article:21531981 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21531981 | pubmed:day | 23 | lld:pubmed |
| pubmed-article:21531981 | pubmed:volume | 117 | lld:pubmed |
| pubmed-article:21531981 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21531981 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21531981 | pubmed:pagination | 6825-36 | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:meshHeading | pubmed-meshheading:21531981... | lld:pubmed |
| pubmed-article:21531981 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21531981 | pubmed:articleTitle | Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived ?-glucans. | lld:pubmed |
| pubmed-article:21531981 | pubmed:affiliation | Division of Hematology/Oncology, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. | lld:pubmed |
| pubmed-article:21531981 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21531981 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21531981 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:12266 | entrezgene:pubmed | pubmed-article:21531981 | lld:entrezgene |
| entrez-gene:16409 | entrezgene:pubmed | pubmed-article:21531981 | lld:entrezgene |
| entrez-gene:56644 | entrezgene:pubmed | pubmed-article:21531981 | lld:entrezgene |
